Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.

Date publication

juillet 2022

Journal

Annals of the rheumatic diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Dr GRANEL-BROCARD Florence

Tous les auteurs :
Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, Lebbe C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35788496

Résumé

To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma.

Mots clés

autoimmunity, immune system diseases, therapeutics

Référence

Ann Rheum Dis. 2022 07 4;: